Wintrust Investments LLC Purchases 735 Shares of Edwards Lifesciences Co. (NYSE:EW)

Wintrust Investments LLC boosted its position in Edwards Lifesciences Co. (NYSE:EW) by 6.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,770 shares of the medical research company’s stock after purchasing an additional 735 shares during the period. Wintrust Investments LLC’s holdings in Edwards Lifesciences were worth $1,110,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Tekla Capital Management LLC raised its stake in shares of Edwards Lifesciences by 10.8% during the second quarter. Tekla Capital Management LLC now owns 189,597 shares of the medical research company’s stock valued at $17,885,000 after acquiring an additional 18,451 shares in the last quarter. Cetera Investment Advisers increased its holdings in Edwards Lifesciences by 5.3% during the second quarter. Cetera Investment Advisers now owns 48,586 shares of the medical research company’s stock valued at $4,583,000 after buying an additional 2,439 shares during the period. Burney Co. increased its holdings in Edwards Lifesciences by 5.8% during the second quarter. Burney Co. now owns 4,253 shares of the medical research company’s stock valued at $401,000 after buying an additional 235 shares during the period. Humankind Investments LLC purchased a new position in Edwards Lifesciences in the second quarter worth $335,000. Finally, Dimensional Fund Advisors LP grew its holdings in Edwards Lifesciences by 1.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,111,893 shares of the medical research company’s stock worth $104,875,000 after purchasing an additional 11,368 shares during the last quarter. Institutional investors own 79.25% of the company’s stock.

Edwards Lifesciences Stock Up 1.9 %

EW stock opened at $67.01 on Thursday. The stock has a market capitalization of $40.64 billion, a P/E ratio of 28.64, a P/E/G ratio of 3.60 and a beta of 1.02. The firm has a 50-day simple moving average of $69.40 and a 200-day simple moving average of $79.88. The company has a quick ratio of 2.45, a current ratio of 3.28 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $94.87.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, October 25th. The medical research company reported $0.59 EPS for the quarter, hitting analysts’ consensus estimates of $0.59. The business had revenue of $1.48 billion during the quarter, compared to analysts’ expectations of $1.48 billion. Edwards Lifesciences had a net margin of 24.59% and a return on equity of 24.54%. The company’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.61 earnings per share. Equities analysts forecast that Edwards Lifesciences Co. will post 2.51 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,500 shares of the company’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $76.69, for a total transaction of $115,035.00. Following the completion of the sale, the vice president now owns 23,950 shares of the company’s stock, valued at approximately $1,836,725.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $77.79, for a total value of $564,366.45. Following the completion of the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,497,301.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Daveen Chopra sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $76.69, for a total transaction of $115,035.00. Following the completion of the transaction, the vice president now owns 23,950 shares in the company, valued at $1,836,725.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 179,795 shares of company stock valued at $12,724,914. Corporate insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on EW. Truist Financial cut their price target on shares of Edwards Lifesciences from $83.00 to $76.00 and set a “buy” rating on the stock in a report on Thursday, October 26th. Stifel Nicolaus cut their price target on shares of Edwards Lifesciences from $87.00 to $70.00 and set a “hold” rating on the stock in a report on Thursday, October 26th. Citigroup cut their price target on shares of Edwards Lifesciences from $94.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, October 26th. Wells Fargo & Company dropped their price objective on shares of Edwards Lifesciences from $88.00 to $75.00 and set an “equal weight” rating on the stock in a report on Thursday, October 26th. Finally, StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $84.29.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.